Daito Pharmaceutical Co.,Ltd. (4577.T)
JPY 2096.0
(0.77%)
JPY 2096.0
(0.77%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 3.89 Billion JPY | -25.22% |
| 2022 | 5.2 Billion JPY | -20.54% |
| 2021 | 6.55 Billion JPY | 10.9% |
| 2020 | 5.9 Billion JPY | 10.29% |
| 2019 | 5.35 Billion JPY | 17.81% |
| 2018 | 4.54 Billion JPY | 9.28% |
| 2017 | 4.16 Billion JPY | 8.58% |
| 2016 | 3.83 Billion JPY | 7.77% |
| 2015 | 3.55 Billion JPY | 1.05% |
| 2014 | 3.51 Billion JPY | 19.74% |
| 2013 | 2.93 Billion JPY | 9.71% |
| 2012 | 2.67 Billion JPY | 1.99% |
| 2011 | 2.62 Billion JPY | 34.09% |
| 2010 | 1.95 Billion JPY | 35.01% |
| 2009 | 1.45 Billion JPY | 8.4% |
| 2008 | 1.33 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 850 Million JPY | 7.73% |
| 2023 Q3 | 815 Million JPY | -32.59% |
| 2023 Q4 | 789 Million JPY | -3.19% |
| 2023 FY | 3.89 Billion JPY | -25.22% |
| 2023 Q2 | 1.2 Billion JPY | 11.94% |
| 2023 Q1 | 1.08 Billion JPY | -1.91% |
| 2022 Q3 | 1.28 Billion JPY | -3.4% |
| 2022 Q1 | 1.5 Billion JPY | 65.5% |
| 2022 Q2 | 1.32 Billion JPY | -11.73% |
| 2022 FY | 5.2 Billion JPY | -20.54% |
| 2022 Q4 | 1.1 Billion JPY | -13.98% |
| 2021 Q4 | 906.97 Million JPY | -48.73% |
| 2021 Q1 | 2.36 Billion JPY | 312.7% |
| 2021 Q2 | 1.51 Billion JPY | -35.74% |
| 2021 FY | 6.55 Billion JPY | 10.9% |
| 2021 Q3 | 1.76 Billion JPY | 16.62% |
| 2020 Q2 | 1.56 Billion JPY | -19.64% |
| 2020 Q3 | 1.82 Billion JPY | 16.61% |
| 2020 Q4 | 571.93 Million JPY | -68.66% |
| 2020 Q1 | 1.94 Billion JPY | 151.96% |
| 2020 FY | 5.9 Billion JPY | 10.29% |
| 2019 Q1 | 1.35 Billion JPY | 53.87% |
| 2019 FY | 5.35 Billion JPY | 17.81% |
| 2019 Q2 | 1.47 Billion JPY | 8.59% |
| 2019 Q3 | 1.75 Billion JPY | 19.11% |
| 2019 Q4 | 772.86 Million JPY | -55.95% |
| 2018 Q3 | 1.33 Billion JPY | 8.43% |
| 2018 Q2 | 1.23 Billion JPY | 12.8% |
| 2018 Q4 | 881.7 Million JPY | -34.1% |
| 2018 FY | 4.54 Billion JPY | 9.28% |
| 2018 Q1 | 1.09 Billion JPY | 12.09% |
| 2017 Q3 | 919.82 Million JPY | -31.02% |
| 2017 Q1 | 932.09 Million JPY | 23.26% |
| 2017 FY | 4.16 Billion JPY | 8.58% |
| 2017 Q4 | 975.82 Million JPY | 6.09% |
| 2017 Q2 | 1.33 Billion JPY | 43.05% |
| 2016 Q1 | 929.82 Million JPY | 15.17% |
| 2016 FY | 3.83 Billion JPY | 7.77% |
| 2016 Q4 | 756.22 Million JPY | -20.37% |
| 2016 Q3 | 949.61 Million JPY | -20.63% |
| 2016 Q2 | 1.19 Billion JPY | 28.68% |
| 2015 FY | 3.55 Billion JPY | 1.05% |
| 2015 Q1 | 968.28 Million JPY | -13.94% |
| 2015 Q4 | 807.34 Million JPY | -10.11% |
| 2015 Q3 | 898.16 Million JPY | 1.83% |
| 2015 Q2 | 882.05 Million JPY | -8.91% |
| 2014 Q4 | 1.12 Billion JPY | 82.82% |
| 2014 Q1 | 717.21 Million JPY | -16.81% |
| 2014 Q2 | 1.06 Billion JPY | 47.95% |
| 2014 FY | 3.51 Billion JPY | 19.74% |
| 2014 Q3 | 615.45 Million JPY | -42.0% |
| 2013 Q4 | 862.11 Million JPY | 59.18% |
| 2013 FY | 2.93 Billion JPY | 9.71% |
| 2013 Q3 | 541.61 Million JPY | -38.64% |
| 2013 Q1 | 652.49 Million JPY | -21.97% |
| 2013 Q2 | 882.71 Million JPY | 35.28% |
| 2012 Q3 | 451.96 Million JPY | -39.2% |
| 2012 FY | 2.67 Billion JPY | 1.99% |
| 2012 Q2 | 743.3 Million JPY | 14.81% |
| 2012 Q1 | 647.44 Million JPY | -1.9% |
| 2012 Q4 | 836.17 Million JPY | 85.01% |
| 2011 Q1 | 525.01 Million JPY | 27.74% |
| 2011 FY | 2.62 Billion JPY | 34.09% |
| 2011 Q2 | 998.59 Million JPY | 90.2% |
| 2011 Q3 | 442.99 Million JPY | -55.64% |
| 2011 Q4 | 659.95 Million JPY | 48.97% |
| 2010 Q1 | 319.08 Million JPY | 0.0% |
| 2010 Q3 | 565.24 Million JPY | -14.11% |
| 2010 FY | 1.95 Billion JPY | 35.01% |
| 2010 Q4 | 411 Million JPY | -27.29% |
| 2010 Q2 | 658.12 Million JPY | 106.25% |
| 2009 Q2 | 501.93 Million JPY | 0.0% |
| 2009 FY | 1.45 Billion JPY | 8.4% |
| 2008 FY | 1.33 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 5.11 Billion JPY | 23.841% |
| Takeda Pharmaceutical Company Limited | 214.07 Billion JPY | 98.181% |
| Sumitomo Pharma Co., Ltd. | -354.19 Billion JPY | 101.099% |
| Shionogi & Co., Ltd. | 171.46 Billion JPY | 97.729% |
| Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | 2091.704% |
| Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | 87.593% |
| Kaken Pharmaceutical Co., Ltd. | 9.51 Billion JPY | 59.067% |
| Eisai Co., Ltd. | 53.4 Billion JPY | 92.709% |
| Morishita Jintan Co., Ltd. | 716 Million JPY | -443.855% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | 70.426% |
| Mochida Pharmaceutical Co., Ltd. | 5.8 Billion JPY | 32.897% |
| Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | -98.269% |
| Nippon Chemiphar Co., Ltd. | -494 Million JPY | 888.259% |
| Tsumura & Co. | 20.01 Billion JPY | 80.548% |
| Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | 3.062% |
| Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | 22.677% |
| Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | 77.935% |
| Fuji Pharma Co., Ltd. | 3.85 Billion JPY | -0.933% |
| Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | 59.924% |
| KYORIN Holdings, Inc. | 6.01 Billion JPY | 35.24% |
| Taiko Pharmaceutical Co.,Ltd. | -3.07 Billion JPY | 226.47% |
| SymBio Pharmaceuticals Limited | -811.66 Million JPY | 579.753% |
| MedRx Co., Ltd | -933 Million JPY | 517.363% |
| Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | 24.418% |
| Solasia Pharma K.K. | -1.13 Billion JPY | 441.879% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 264.304% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 6.5 Billion JPY | 40.092% |
| Sawai Group Holdings Co., Ltd. | 18.88 Billion JPY | 79.382% |
| Cyfuse Biomedical K.K. | -697.43 Million JPY | 658.33% |
| Toho Holdings Co., Ltd. | 19.33 Billion JPY | 79.856% |
| Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | 11.143% |